Physician profile
Janna Chen
NPI 1003923509
$3,121.80
in general payments reported to CMS, 2019-2025
22 companies · $879 in 2025
The $879 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $285 · 2021: $252 · 2022: $294 · 2023: $365 · 2024: $538 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $592.98 | 2019-2024 | Omni Surgical System, Tearcare System |
| Dompe US, INC. | $314.19 | 2024-2025 | Oxervate |
| Alcon Vision LLC | $263.04 | 2022-2025 | Clareon, Tryptyr, Rocklatan |
| Sun Pharmaceutical Industries INC. | $256.87 | 2019-2023 | Cequa |
| Novartis Pharmaceuticals Corporation | $252.42 | 2019-2023 | |
| Harrow Eye, LLC | $251.05 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $231.76 | 2022-2025 | Xiidra, Miebo, Envista Envy Iol |
| Rxsight INC | $134.82 | 2021-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Ivantis, INC | $133.93 | 2020 | |
| Shire North American Group INC | $114.93 | 2019 | |
| Oyster Point Pharma, INC. | $100.87 | 2022-2025 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $95.47 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $77.01 | 2024-2025 | Purified Cortrophin Gel |
| Tarsus Pharmaceuticals, INC. | $68.91 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $66.57 | 2020-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $65.58 | 2019-2021 | |
| Thea Pharma INC. | $23.16 | 2024 | Iyuzeh |
| Alimera Sciences, INC. | $17.14 | 2021 | |
| Coopervision INC. | $16.71 | 2024 | Paragon Crt |
| Kala Pharmaceuticals, INC. | $15.65 | 2021 | |
| Aerie Pharmaceuticals, INC. | $14.54 | 2021 | |
| Mallinckrodt Hospital Products INC. | $14.20 | 2023 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janna Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.